Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | SVP, CHIEF LEGAL OFFICER, SECY | May 25, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SANGAMO THERAPEUTICS, INC
Report date May 25, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 647,370 |
Reported balance
After 2026-05-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-25 · Tax withholding · Disposed 4,036 · Balance 647,370 F1: Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2: Includes: 7,214 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 78,750 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2: Includes: 7,214 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 78,750 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2026 Filed May 27, 2026 23:30 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 4,036 | $0.17 | $703.47 |
DisclosureSEC source: 0001877368-26-000008 · form4-05272026_070504.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,370 F1 · shares: Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: 7,214 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 78,750 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:15 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001877368-26-000006 · form4-04032026_040405.xml · derivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 02:40 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 12,354 | $0.47 | $5,806.38 |
DisclosureSEC source: 0001877368-26-000004 · form4-02262026_090207.xml · nonDerivative · entry 2 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 651,406 F3 · shares: Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F4 · balance_after: Includes: 17,646 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 90,000 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 02:40 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,650 | $0.47 | $779.63 |
DisclosureSEC source: 0001877368-26-000004 · form4-02262026_090207.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 663,760 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,358 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 36,676 | $0.40 | $14,615.39 |
DisclosureSEC source: 0001877368-26-000002 · form4-01262026_090103.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 665,410 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 4,008 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 2,035 | $0.42 | $847.78 |
DisclosureSEC source: 0001877368-25-000007 · form4-11262025_091119.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 702,086 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 1,973 shares resulting from the November 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 4,008 shares will vest on February 24, 2026, (b) 89,063 shares subject to Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 21:00 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 44,122 | $0.66 | $29,120.52 |
DisclosureSEC source: 0001877368-25-000005 · form4-10242025_051009.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 704,121 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 44,940 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 8,016 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 24, 2025 Filed Aug 27, 2025 00:01 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,434 | $0.59 | $840.75 |
DisclosureSEC source: 0001415889-25-023077 · form4-08272025_120830.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 748,243 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,574 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 8,016 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 178,125 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:57 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 31,866 | $0.48 | $15,289.31 |
DisclosureSEC source: 0001415889-25-020244 · form4-07242025_080724.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 749,677 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 57,197 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 178,125 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 12,024 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 24, 2025 Filed May 28, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,433 | $0.47 | $678.24 |
DisclosureSEC source: 0001415889-25-014695 · form4-05282025_040508.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, CHIEF LEGAL OFFICER, SECY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 781,543 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,574 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 12,024 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 267,188 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 20:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 31,866 | $0.78 | $24,737.58 |
DisclosureSEC source: 0001415889-25-011287 · form4-04242025_080444.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 782,976 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 57,196 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 267,188 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 16,031 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 22:32 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 560,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001415889-25-005706 · form4-02262025_100200.xml · derivative · entry 4 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires 2035-02-24 F7 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 22:32 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005706 · form4-02262025_100200.xml · nonDerivative · entry 3 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814,842 F5 · shares: Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F6 · balance_after: Includes: (a) 16,031 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 22:32 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,375 | $0.96 | $1,314.64 |
DisclosureSEC source: 0001415889-25-005706 · form4-02262025_100200.xml · nonDerivative · entry 2 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 694,842 F3 · shares: Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F4 · balance_after: Includes: (a) 2,469 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 16,031 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 22:32 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,434 | $1.00 | $1,434.00 |
DisclosureSEC source: 0001415889-25-005706 · form4-02262025_100200.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 696,217 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,574 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 16,031 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 3,844 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 129,549 | $1.15 | $148,981.35 |
DisclosureSEC source: 0001415889-25-002021 · form4-01242025_040110.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,651 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2025 of $1.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 226,701 shares resulting from the January 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 356,250 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 3,844 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,371 | $1.94 | $2,659.74 |
DisclosureSEC source: 0001415889-24-027705 · form4-11262024_091107.xml · nonDerivative · entry 2 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 827,200 F4 · shares: Represents shares underlying the portion of an RSU grant that vested on November 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 25, 2024 of $1.94/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes: (a) 2,473 shares resulting from the November 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 3,844 shares will vest in one final installment on February 25, 2025, (b) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| November 24, 2024 Filed Nov 26, 2024 21:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,430 | $1.88 | $2,688.40 |
DisclosureSEC source: 0001415889-24-027705 · form4-11262024_091107.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,571 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 22, 2024 of $1.88/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,578 shares resulting from the November 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 20,039 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 7,688 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025 and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 25, 2024 Filed Aug 27, 2024 20:38 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,371 | $0.86 | $1,179.06 |
DisclosureSEC source: 0001415889-24-022312 · form4-08272024_080842.xml · nonDerivative · entry 2 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,001 F4 · shares: Represents shares underlying the portion of an RSU grant that vested on August 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 23, 2024 of $0.86/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes: (a) 2,473 shares resulting from the August 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 7,688 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 24,047 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| August 24, 2024 Filed Aug 27, 2024 20:38 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,430 | $0.86 | $1,229.80 |
DisclosureSEC source: 0001415889-24-022312 · form4-08272024_080842.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 831,372 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 23, 2024 of $0.86/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,578 shares resulting from the August 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 24,047 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 11,532 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025 and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:34 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 892 | $0.98 | $869.79 |
DisclosureSEC source: 0001415889-24-021365 · form4-08152024_080821.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 832,802 F1 · shares: Represents shares underlying the portion of a Restricted Stock Unit ("RSU") grant that vested on August 13, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 13, 2024 of $0.9751/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 1,608 shares resulting from the August 13, 2024 final vesting installment of the Reporting Person's August 13, 2021 RSU grant, (b) 11,532 shares subject to Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 28,055 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (d) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 25, 2024 Filed May 29, 2024 21:15 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,336 | $0.60 | $801.60 |
DisclosureSEC source: 0001415889-24-014796 · form4-05292024_090552.xml · nonDerivative · entry 2 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833,694 F4 · shares: Represents shares underlying the portions of RSU grants that vested on May 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes: (a) 2,507 shares resulting from the May 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 11,532 shares will vest in successive equal quarterly installments through February 25, 2025, (c) 28,055 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (c) 2,500 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in one final installment on August 13, 2024 and (e) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:15 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,400 | $0.60 | $840.00 |
DisclosureSEC source: 0001415889-24-014796 · form4-05292024_090552.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 835,030 F1 · shares: Represents shares underlying the portions of RSU grants that vested on May 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,607 shares resulting from the May 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 28,055 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 15,375 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 2,500 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in one final installment on August 13, 2024 and (e) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2024 Filed Feb 27, 2024 22:13 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 3,453 | $1.13 | $3,901.89 |
DisclosureSEC source: 0001415889-24-005550 · form4-02272024_100241.xml · nonDerivative · entry 2 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 836,430 F4 · shares: Represents shares underlying the portions of RSU grants that vested on February 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes: (a) 2,706 shares resulting from the February 25, 2024 final vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 2,269 shares resulting from the February 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 15,375 shares will vest in successive equal quarterly installments through February 25, 2025, (c) 32,062 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (d) 2,500 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in one final installment on August 13, 2024 and (e) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| February 24, 2024 Filed Feb 27, 2024 22:13 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 4,379 | $1.13 | $4,948.27 |
DisclosureSEC source: 0001415889-24-005550 · form4-02272024_100241.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 839,883 F1 · shares: Represents shares underlying the portions of RSU grants that vested on February 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 6,309 shares resulting from the February 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 32,062 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (c) 19,219 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (d) 2,500 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in one final installment on August 13, 2024 and (e) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:42 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 712,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001757 · form4-01242024_090106.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, GEN. COUNSEL & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 844,262 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration in full in the event of a Change in Control (as defined in the 2018 EIP). F2 · balance_after: Includes: (a) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (b) 19,219 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 42,750 shares subject to the Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter and (d) 2,500 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in one final installment on August 13, 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F3 · balance_after: Includes 5,000 shares acquired on November 30, 2023 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| November 25, 2023 Filed Nov 28, 2023 21:20 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,329 | $0.38 | $507.81 |
DisclosureSEC source: 0001209191-23-056791 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,762 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,515 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 19,219 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (c) 42,750 shares subject to the Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter and (see footnote 3) F3 · balance_after: (d) 2,500 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in one final installment on August 13, 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 20:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,329 | $0.77 | $1,023.33 |
DisclosureSEC source: 0001209191-23-047577 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,091 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 25, 2023 of $0.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,515 shares resulting from the August 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 23,063 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (c) 42,750 shares subject to the Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter and (see footnote 3) F3 · balance_after: (d) 2,500 shares the Reporting Person's August 13, 2021 RSU grant that will vest in one final installment on August 13, 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 13, 2023 Filed Aug 15, 2023 20:55 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 864 | $1.08 | $933.12 |
DisclosureSEC source: 0001209191-23-045879 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,420 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 13, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 11, 2023 of $1.08/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 1,636 shares resulting from the August 13, 2023 vesting installment of the Reporting Person's August 13, 2021 RSU grant and 2,500 shares subject to such RSU grant that will vest in one final installment on August 13, 2024, (b) 26,907 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (see footnote 3) F3 · balance_after: (d) 42,750 shares subject to the Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F4 · balance_after: Includes 5,000 shares acquired on May 31, 2023 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:45 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,328 | $1.33 | $1,766.24 |
DisclosureSEC source: 0001209191-23-032914 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,284 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,515 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 26,907 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 5,000 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in two remaining installments of 2,500 shares on each of August 13, 2023 and 2024, (c) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (continued in footnote 3) F3 · balance_after: (d) 42,750 shares subject to the Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 21:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 3,977 | $1.65 | $6,562.05 |
DisclosureSEC source: 0001209191-23-025721 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,612 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 24, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 24, 2023 of $1.65/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 7,525 shares resulting from the April 24, 2023 final vesting installment of the Reporting Person's April 24, 2020 RSU grant, (b) 5,000 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in two remaining installments of 2,500 shares on each of August 13, 2023 and 2024, (c) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (continued in footnote 3) F3 · balance_after: (d) 30,750 shares subject to Reporting Person's February 25, 2022 RSU grant that will vest in 8 successive equal quarterly installments after February 25, 2023 and (e) 42,750 shares subject to the Reporting Person's February 25, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2023 Filed Mar 6, 2023 22:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 5,128 | $2.66 | $13,640.48 |
DisclosureSEC source: 0001209191-23-016399 · doc4.xml · nonDerivative · entry 2 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,589 F3 · shares: Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes 1 share acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. F4 · balance_after: Includes: (a) 2,999 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 4,584 shares subject to such RSU grant that will vest in one final installment on February 25, 2024, (b) 6,706 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 30,750 shares will vest in 8 successive equal quarterly installments thereafter, (continued in footnote 5) F5 · balance_after: (c) 11,502 shares subject to the Reporting Person's April 24, 2020 RSU grant that will vest in one final installment on April 24, 2023 and (d) 5,000 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in two remaining installments of 2,500 shares on each of August 13, 2023 and 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 199,500 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-23-016399 · doc4.xml · derivative · entry 3 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,500 Underlying: Common Stock · 199,500 shares Expires 2033-02-23 F6 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 42,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016399 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,717 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 1 share acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| August 13, 2022 Filed Aug 16, 2022 21:58 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 864 | $6.33 | $5,469.12 |
DisclosureSEC source: 0001209191-22-046022 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,966 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 13, 2022 which were surrendered by the Reporting Person to the Issuer solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 12, 2022 of $6.33/share pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 1,636 shares resulting from the August 13, 2022 annual vesting installment of the Reporting Person's August 13, 2021 RSU grant and 5,000 shares subject to such RSU grant that will vest in two remaining annual installments of 2,500 shares on each of August 13, 2023 and 2024, (b) 9,167 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (c) 11,502 shares subject to the Reporting Person's April 24, 2020 RSU grant that will vest in one final annual installment on April 24, 2023, and (See footnote 3) F3 · balance_after: (d) 41,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F4 · balance_after: Includes 3,121 shares acquired on May 31, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| April 29, 2022 Filed May 3, 2022 21:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 140 | $4.15 | $581.00 |
DisclosureSEC source: 0001209191-22-026801 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,709 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 29, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on April 29, 2022 of $4.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 265 shares resulting from the April 29, 2022 final annual vesting installment of the Reporting Person's April 29, 2022 RSU grant, (b) 7,500 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in three annual installments of 2,500 shares on each of August 13, 2022, 2023 and 2024, (c) 9,167 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (d) 11,502 shares subject to the Reporting Person's April 24, 2020 RSU grant that will vest in one final annual installment on April 24, 2023, and (See footnote 3) F3 · balance_after: (e) 41,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| April 24, 2022 Filed Apr 26, 2022 21:37 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 3,976 | $4.70 | $18,687.20 |
DisclosureSEC source: 0001209191-22-025671 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,849 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 24, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on April 22, 2022 of $4.70/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 7,523 shares resulting from the April 24, 2022 vesting of the Reporting Person's April 24, 2020 RSU grant and 11,502 shares subject to such RSU grant that will vest in one final annual installment on April 24, 2023, (b) 405 shares subject to the Reporting Person's November 10, 2020 RSU grant that will vest in one final installment on April 29, 2022, (c) 7,500 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in three annual installments of 2,500 shares on each of August 13, 2022, 2023 and 2024, (d) 9,167 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, and (See footnote 3) F3 · balance_after: (e) 41,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 110,700 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014179 · doc4.xml · derivative · entry 3 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,700 Underlying: Common Stock · 110,700 shares Expires 2032-02-24 F6 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 41,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014179 · doc4.xml · nonDerivative · entry 2 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,825 F5 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,566 | $5.90 | $9,239.40 |
DisclosureSEC source: 0001209191-22-014179 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,825 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 3,017 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 9,167 shares subject to such RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (b) 23,001 shares subject to the Reporting Person's April 24, 2020 RSU grant that will vest in two remaining annual installments of 11,499 shares and 11,502 shares on April 24, 2022 and 2023, respectively, (c) 405 shares subject to the Reporting Person's November 10, 2020 RSU grant that will vest in one final installment on April 29, 2022 and (d) 7,500 shares subject to the Reporting Person's August 13, 2021 RSU grant that will vest in three annual installments of 2,500 shares on each of August 13, 2022, 2023 and 2024. See footnote 3. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F4 · balance_after: Includes 936 shares acquired on November 30, 2021 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| October 29, 2021 Filed Nov 3, 2021 19:30 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 140 | $8.12 | $1,136.80 |
DisclosureSEC source: 0001209191-21-062653 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,455 F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on October 29, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on October 29, 2021 of $8.12/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 265 shares of common stock resulting from the October 29, 2021 vesting of the Reporting Person's November 10, 2020 RSU grant and 405 shares of common stock subject to such RSU grant that will vest in one remaining installment on April 29, 2022; (b) 23,001 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on April 24, 2020 that will vest in two remaining annual installments on April 24, 2022 and 2023 respectively; (continued in Footnote 3) F3 · balance_after: Continued from Footnote 2 - (c) 13,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021; and (d) 7,500 shares of common stock subject to RSUs granted to the Reporting Person on August 1, 2021. All such RSUs vest with respect to 1/3rd of the shares granted in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended), through such dates and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 21:57 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001209191-21-051997 · doc4.xml · derivative · entry 2 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-08-12 F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the August 13, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended), through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 21:57 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-051997 · doc4.xml · nonDerivative · entry 1 Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,595 F1 · shares: Represents 7,500 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on August 13, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such dates and subject to acceleration as provided in the 2018 EIP, as amended. F2 · balance_after: Includes: (a) 23,001 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on April 24, 2020; and (b) 13,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021. All such RSUs vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended), through such dates and subject to acceleration as provided in the 2018 EIP, as amended. F3 · balance_after: Includes 810 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on November 10, 2020. The RSUs will vest in two equal remaining installments on October 29, 2021 and April 29, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended), through such dates and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.